Alpha Tau Medical Ltd. (DRTS)
Nasdaq · Healthcare · Biotechnology
$14.89+0.81%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.4B
- 52-week range
- $3.43 – $15.79
- 52-week change
- +250.00%
- EPS (trailing)
- −$1.04
- Next earnings
- Nov 19, 2026
Fiscal year to Dec 2025
- Net income
- −$42.6M
- Diluted EPS
- −$0.53
- Free cash flow
- −$32.8M
From the company’s annual report on SEC EDGAR.
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Headquarters: Jerusalem, Israel · 121 employees · alphatau.com